Recursion Pharmaceuticals (RXRX) News Today → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free RXRX Stock Alerts $9.42 -0.09 (-0.95%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 8:59 PM | marketbeat.comNikko Asset Management Americas Inc. Has $90.57 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Nikko Asset Management Americas Inc. grew its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 161.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,203,780 shares of the company's stockMay 17 at 9:16 AM | finance.yahoo.comDirector Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals Inc (RXRX)May 16 at 6:09 PM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.4%Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.4%May 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)May 14, 2024 | marketbeat.comThe Next Drug You Take May be Designed By A.I. (RXRX)Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030May 14, 2024 | americanbankingnews.comRecursion Pharmaceuticals' (RXRX) Buy Rating Reiterated at Needham & Company LLCMay 13, 2024 | msn.comRecursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor OptimismMay 13, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading VolumeRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume IncreaseMay 13, 2024 | marketwatch.comRecursion Pharmaceuticals Shares Rise 14% on New Nvidia-Powered SupercomputerMay 13, 2024 | globenewswire.comRecursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical IndustryMay 12, 2024 | fool.comCathie Wood Is Buying This Under-the-Radar AI StockMay 11, 2024 | finance.yahoo.comRecursion Pharmaceuticals First Quarter 2024 Earnings: Beats ExpectationsMay 11, 2024 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up on Better-Than-Expected EarningsMay 10, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPSRecursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The firm had revenue of $13.80 million for the quarter, compared to analysts' expectations of $11.10 million. During the same quarter last year, the company posted ($0.34) earnings per share. Recursion Pharmaceuticals's revenue was up 14.0% on a year-over-year basis.May 10, 2024 | msn.comRecursion Pharmaceuticals CEO explains how AI could make drug development faster and less costlyMay 10, 2024 | fool.comRecursion Pharma's Q1 Earnings Beat EstimatesMay 10, 2024 | markets.businessinsider.comDemystifying Recursion Pharmaceuticals: Insights From 4 Analyst ReviewsMay 10, 2024 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comRecursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue Surpasses Estimates Amid ...May 10, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Earnings BeatRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up on Better-Than-Expected EarningsMay 10, 2024 | marketbeat.comRecursion Pharmaceuticals' (RXRX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Friday.May 9, 2024 | markets.businessinsider.comRXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comRecursion Provides Business Updates and Reports First Quarter 2024 Financial ResultsMay 6, 2024 | msn.comRecursion (RXRX) to Report Q1 Earnings: What's in the Cards?May 6, 2024 | msn.comNvidia and a FTSE 100 fund own a 10% stake in this $8 artificial intelligence (AI) stockMay 4, 2024 | marketbeat.comVestmark Advisory Solutions Inc. Purchases Shares of 472,256 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Vestmark Advisory Solutions Inc. bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 472,256 shares of the company's stock, valued at approximMay 4, 2024 | insidertrades.comInsider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells 50,000 Shares of StockMay 3, 2024 | marketbeat.comRecursion Pharmaceuticals (RXRX) Scheduled to Post Earnings on ThursdayRecursion Pharmaceuticals (NASDAQ:RXRX) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 3, 2024 | insidertrades.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 11,447 SharesMay 2, 2024 | globenewswire.comRecursion to Report First Quarter 2024 Business Updates and Financial Results on May 9May 1, 2024 | globenewswire.comRecursion to Participate in Upcoming Investor ConferencesApril 30, 2024 | finance.yahoo.comAltitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering ProgramApril 30, 2024 | insidertrades.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells $23,010.00 in StockApril 29, 2024 | marketbeat.comInsider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells 3,000 Shares of StockRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) COO Tina Marriott sold 3,000 shares of the business's stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $7.67, for a total value of $23,010.00. Following the sale, the chief operating officer now owns 543,231 shares of the company's stock, valued at approximately $4,166,581.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.April 27, 2024 | investorplace.comThe Top 3 Biotech Stocks to Buy in April 2024April 26, 2024 | benzinga.comRecursion Pharmaceuticals's Options Frenzy: What You Need to KnowApril 20, 2024 | investing.comRecursion Pharmaceuticals CFO sells shares worth over $367kApril 19, 2024 | insidertrades.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 23,124 SharesApril 18, 2024 | marketbeat.comInsider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells 11,447 Shares of StockRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total transaction of $87,684.02. Following the transaction, the director now owns 7,229,861 shares of the company's stock, valued at approximately $55,380,735.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.April 18, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Buys 5,680,656 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Sumitomo Mitsui Trust Holdings Inc. increased its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 161.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 9,203,780 shares of the company's stock after purchasing an additionalApril 17, 2024 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should KnowApril 17, 2024 | finanznachrichten.deRecursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerApril 17, 2024 | fool.comWhere Will Recursion Pharmaceuticals Be in 5 Years?April 16, 2024 | globenewswire.comRecursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerApril 15, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.6%Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.6%April 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 10, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - RXRXApril 10, 2024 | seekingalpha.comRevisiting Recursion: Big Bets, Big Data, And The Big Cash Burn RateApril 10, 2024 | marketbeat.comBaillie Gifford & Co. Sells 371,905 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Baillie Gifford & Co. reduced its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,179,504 shares of the company'sApril 10, 2024 | fool.comCan Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Bible Shocker: Have You Seen Elon Musk’s Miracle? (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process. Click here for the full story… RXRX Media Mentions By Week RXRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.440.42▲Average Medical News Sentiment RXRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼115▲RXRX Articles Average Week Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Ginkgo Bioworks News Today Sana Biotechnology News Today Apogee Therapeutics News Today CG Oncology News Today Beam Therapeutics News Today Fusion Pharmaceuticals News Today Inhibrx News Today Kymera Therapeutics News Today Vericel News Today Denali Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
